What should you know about tofacitinib granuloma annulare?

Granuloma annulare is an inflammatory skin condition that can form ring-shaped groups of firm bumps. It is not the same as a fungal ring rash, so the appearance should be assessed before treatment begins. The extent, location, symptoms, and effect on daily life help determine the treatment discussion.

Tofacitinib changes signalling inside immune cells. Use for granuloma annulare may be outside the medicine's routine labelled uses, so it requires an individual prescription and monitoring plan. A dermatologist will review other medicines, infections, medical conditions, pregnancy plans, and vaccination history before considering it.

Do not start, stop, or alter tofacitinib without the prescribing clinician. Keep a record of new bumps, spread, itch, pain, and any change after treatment starts. Tell the clinician about fever, recent infection, unexplained symptoms, or medicines that affect the immune system.

Depending on the pattern, a dermatologist may discuss local options such as [Steroid Injection Into The Skin](/treatments/injectables/intralesional-steroid-injection/) or [Topical Corticosteroids](/treatments/medical-dermatology/topical-corticosteroids/). The choice depends on the number and position of lesions, skin thickness, previous response, and your general health.

Contact the prescribing team promptly if you develop signs of infection, a persistent fever, unusual shortness of breath, or a rapidly worsening skin reaction. Seek urgent care for severe breathing difficulty, facial swelling, or faintness.

Arrange review if the diagnosis is uncertain, lesions are spreading quickly, or treatment is not tolerated. New skin changes should not automatically be attributed to granuloma annulare, particularly when they look unlike the original rings.

Ask why tofacitinib is being considered, what alternatives fit your pattern, which checks are needed before and during treatment, and what symptoms require a same-day call. Ask how progress will be judged and when the plan will be reassessed.